Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€2.10

€2.10

-3.810%
-0.08
-3.810%
-
 
09.05.25 / Tradegate WKN: 520394 / Name: B.R.A.I.N. Biotechnology / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:

B.R.A.I.N. Biotechnology Research and Information Network AG Stock

B.R.A.I.N. Biotechnology Research and Information Network AG took a tumble today and lost -€0.080 (-3.810%).

Pros and Cons of B.R.A.I.N. Biotechnology Research and Information Network AG in the next few years

Pros
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of B.R.A.I.N. Biotechnology Research and Information Network AG vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
B.R.A.I.N. Biotechnology Research and Information Network AG -3.810% -2.778% -10.256% -24.460% -40.000% -72.727% -76.510%
Formycon AG 0.610% 5.128% 11.061% -43.056% -53.143% -60.386% -8.209%
MagForce AG 10.000% 0.000% -15.385% 57.143% 1000.000% -99.725% -99.821%
Ardelyx Inc. -1.480% -11.757% -21.483% -57.396% -35.146% 375.558% -51.579%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-11

Based on the provided financials, it's observed that B.R.A.I.N Biotechnology has an interesting financial perspective. As a company in a rather volatile industry, Biotechnology, the financials of the firm showcase a unique blend of stability and potential areas of growth. However, they also reveal certain risks and possible weaknesses.

Vorteile (Pros)

In terms of market capitalization, B.R.A.I.N Biotechnology seems to be making steady strides. With a market capitalization of approximately 88.7 million, the company appears to have a stable market presence. It's also noteworthy that the company has continuously secured revenue, as indicated by the revenue TTM (Trailing Twelve Months) of 54.698 million.

Comments

Prediction Sell
Perf. (%) -16.22%
Target price
Change
Ends at 21.03.23

Sell B.R.A.I.N. Biotechnology Research and Information Network AG
Show more

Buy B.R.A.I.N. Biotechnology Research and Information Network AG
Show more

Buy B.R.A.I.N. Biotechnology Research and Information Network AG
Show more

News

EQS-Adhoc: BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25
EQS-Adhoc: BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25
EQS-Adhoc: BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25
EQS-News: Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG
EQS-News: Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG
EQS-News: Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG
EQS-News: BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division
EQS-News: BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division
EQS-News: BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division